Compare MCHP & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHP | IQV |
|---|---|---|
| Founded | 1989 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Semiconductors | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.1B | 43.1B |
| IPO Year | 2004 | 2013 |
| Metric | MCHP | IQV |
|---|---|---|
| Price | $71.49 | $269.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 16 |
| Target Price | $85.59 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 7.3M | 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | ★ 2300.00 | 4.67 |
| EPS | 0.37 | ★ 1.61 |
| Revenue | $5,349,500,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $8.12 | $6.77 |
| Revenue Next Year | $22.55 | $5.89 |
| P/E Ratio | $199.81 | ★ $162.59 |
| Revenue Growth | 34.38 | ★ 41.60 |
| 52 Week Low | $48.52 | $154.50 |
| 52 Week High | $105.91 | $271.80 |
| Indicator | MCHP | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 65.29 |
| Support Level | $63.54 | $159.91 |
| Resistance Level | $76.06 | $271.80 |
| Average True Range (ATR) | 1.92 | 6.15 |
| MACD | 0.13 | -1.48 |
| Stochastic Oscillator | 14.72 | 69.82 |
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.